Congress Asset Management Co. Grows Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Congress Asset Management Co. boosted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 908,742 shares of the company's stock after buying an additional 43,619 shares during the quarter. Congress Asset Management Co. owned approximately 1.84% of Prestige Consumer Healthcare worth $70,964,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PBH. Boston Trust Walden Corp purchased a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at approximately $41,785,000. Allspring Global Investments Holdings LLC lifted its stake in Prestige Consumer Healthcare by 19.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company's stock valued at $113,570,000 after buying an additional 255,045 shares in the last quarter. Wellington Management Group LLP purchased a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at approximately $6,342,000. Barclays PLC lifted its stake in Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company's stock valued at $6,665,000 after buying an additional 71,730 shares in the last quarter. Finally, Edgestream Partners L.P. purchased a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at approximately $3,947,000. Hedge funds and other institutional investors own 99.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Oppenheimer increased their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Canaccord Genuity Group raised their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, February 7th. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Friday, January 24th. Sidoti cut Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Finally, Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $92.60.

Prestige Consumer Healthcare Trading Down 0.2 %

Prestige Consumer Healthcare stock traded down $0.19 during midday trading on Wednesday, reaching $85.00. The stock had a trading volume of 323,098 shares, compared to its average volume of 317,639. Prestige Consumer Healthcare Inc. has a twelve month low of $62.35 and a twelve month high of $88.36. The stock has a market capitalization of $4.21 billion, a PE ratio of 19.91, a price-to-earnings-growth ratio of 2.73 and a beta of 0.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The stock's 50-day simple moving average is $79.34 and its 200 day simple moving average is $76.15.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.